EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
EGFR-TKI With Chemotherapy as First Line Treatment in Stage IIIB/IV NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Listed as NCT02859077, this PHASE3 trial focuses on Non-Small-Cell Lung Cancer and remains ongoing. Sponsored by Shanghai Pulmonary Hospital, Shanghai, China, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Pulmonary Hospital, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.